Glenmark Gets US FDA Approval for RYALTRIS Nasal Spray in Kids Aged 6 to Under 12
Glenmark Pharmaceuticals received US FDA approval to expand RYALTRIS Nasal Spray for Seasonal Allergic Rhinitis in pediatric patients aged 6 to less than 12 years, supported by a Phase 3 study of 446 children. The fixed-dose combination nasal spray, initially approved in 2022 for patients aged 12 and older, is now available for a broader age group. Glenmark assumed direct commercialization of RYALTRIS in the US from April 1, 2026, with the product now present in 56 countries globally.
*this image is generated using AI for illustrative purposes only.
Glenmark Pharmaceuticals received approval from the U.S. FDA to expand the use of RYALTRIS Nasal Spray for the treatment of Seasonal Allergic Rhinitis (SAR) in pediatric patients aged 6 to less than 12 years. The approval strengthens the company's innovative respiratory portfolio following its transition to direct commercialization in the United States. RYALTRIS is now approved for adults and pediatric patients aged 6 years and older.
The approval was supported by a Phase 3, randomized, double-blind, placebo-controlled study involving 446 children aged 6 to 11 years with Seasonal Allergic Rhinitis. The study demonstrated that RYALTRIS improved nasal symptoms compared with placebo and was well tolerated over the 14-day treatment period. According to the U.S. Centers for Disease Control and Prevention, 25% of children aged 6 to 11 years had a diagnosed seasonal allergy in 2024.
Effective April 1, 2026, Glenmark Pharmaceuticals Inc., USA assumed responsibility for the end-to-end commercialization and distribution of RYALTRIS in the United States. The company now directly leads the product's brand strategy, market access, distribution, and customer engagement.
Product Details
RYALTRIS is a fixed-dose combination nasal spray containing olopatadine hydrochloride and mometasone furoate. It combines an antihistamine and a corticosteroid in a single formulation. The drug was initially approved by the U.S. FDA in 2022 for adults and pediatric patients 12 years of age and older.
| Feature | Details |
|---|---|
| Indication | Seasonal Allergic Rhinitis |
| Dosage | 665 mcg/25 mcg per spray |
| Initial Approval Year | 2022 |
| New Patient Age Group | 6 to less than 12 years |
Global Presence
RYALTRIS has established a broad international footprint with approvals across key markets including the European Union, United Kingdom, Australia, South Korea, Russia, and China. In FY26, RYALTRIS was launched in 11 additional markets, expanding its global presence to 56 countries.
Marc Kikuchi, President & Business Head, North America, stated that the approval marks an important step in expanding access to RYALTRIS. He added that the transition to direct commercialization enables closer engagement with healthcare professionals and patients to build the franchise.
Historical Stock Returns for Glenmark Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.08% | -5.73% | -0.86% | +11.93% | -0.54% | +223.22% |
How will the transition to direct commercialization impact Glenmark's operating margins and R&D reinvestment capabilities?
What are the projected revenue contributions from the newly approved 6-11 age demographic given the 25% prevalence rate?
Does Glenmark plan to pursue further FDA approvals to expand RYALTRIS into the Perennial Allergic Rhinitis market?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
